- Home
- » Tags
- » Ecallantide
Top View
- Haei Newsletter
- Shire 2016 Investor Day
- Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
- Overview of Ecallantide in the Treatment of Hereditary Angioedema Types I and II
- Avis Du 25 Juillet 2018
- Kalbitor® (Ecallantide)
- Current and Emerging Biologics for the Treatment of Hereditary Angioedema� Francesca Peregoa, Maddalena A
- Who Expert Committee on Specifications for Pharmaceutical Preparations
- Ecallantide (Kalbitor) Reference Number: ERX.SPMN.80 Effective Date: 07/16 Coding Implications Last Review Date: 06/16 Revision Log
- A Mechanistic Model and Therapeutic Interventions for COVID-19
- Product Monograph
- Kalbitor, INN-Ecallantide
- Australian Public Assessment Report for Lanadelumab
- (ACEI) Induced Angioedema by Ecallantide: a Case Report
- Ecallantide Is a Novel Treatment for Attacks of Hereditary Angioedema Due to C1 Inhibitor Deficiency
- 1.4.1. Draft Label- KALBITOR(I 10 OVERDOSAGE
- KALBITOR® Safely and Effectively
- Current Specialty Pharmacy Drugs (As of July 1, 2021*) New Drugs Indicated in Red
- Ecallantide (KALBITOR), Icatibant
- Advantage MD Part B Prior Authorization List
- Hereditary Angioedema Medical Agent Program Summary
- Observational Real-World Evidence Update Prophylaxis Of
- Hereditary Angioedema (HAE) Therapies NOTICE
- ATC Vet 2021 Atccode Atcdescription Atcdescriptionsi QA ALIMENTARY TRACT and METABOLISM ZDRAVILA ZA BOLEZNI PREBAVIL in PRESNOVE
- 2020 Table of Drugs
- Medications to Require Medical Prior Authorization, Effective Jan 1
- [Ehdsi V3.0.0-RC1] Ehealth DSI – Master Value Set Catalogue
- Rxoutlook® 1St Quarter 2021
- Klasifikacija ATC 2021
- Appendix C - Guidelines for IV Medication Administration
- Current Treatment of Angioedema Induced by ACE Inhibitors I Terreehorst, MD, Phd1,* S Reitsma, MD, Phd1 DM Cohn, MD, Phd2
- Kalbitor) Reference Number: ERX.SPA.29 Effective Date: 07.01.16 Last Review Date: 02.21 Line of Business: Commercial, Medicaid Revision Log
- Assessment Report
- Drug Monograph Drug Name: Orladeyo™ (Berotralstat) Capsule Drug Class: Plasma Kallikrein Inhibitor Prepared For: MO Healthnet Prepared By: Conduent
- Hereditary Angioedema
- RX.PA.128.E.MPC REVISION DATE: 02/2020 PAGE NUMBER: 1 of 3
- Ecallantide for the Treatment of Acute Attacks of Hereditary Angioedema Due to C1-Inhibitor Deficiency
- Kalbitor® (Ecallantide) (SQ Formulation)
- Biocryst Pharmaceuticals, Inc
- Subject: Kalbitor (Ecallantide) Original Effective Date: 3/11/10
- Kalbitor®) Office Administration
- ATC Code Title
- Shire Could Reclaim HAE Prophylaxis Market from CSL Behring
- Pharmacology Column Editor: Kyle A